A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/08/2011	US20110300177 Triterpene saponins, methods of synthesis, and uses thereof
12/08/2011	US20110300176 Microorganisms for therapy
12/08/2011	US20110300167 Cxcr5 receptor compounds
12/08/2011	US20110300162 Drug conjugate composition
12/08/2011	US20110300161 Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma
12/08/2011	US20110300160 Sulfation of wnt pathway proteins
12/08/2011	US20110300157 Metalloproteinase 9 and metalloproteinase 2 binding proteins
12/08/2011	US20110300156 Human antibodies against tissue factor
12/08/2011	US20110300152 Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
12/08/2011	US20110300147 Inhibiting tumor cell invasion, metastasis and angiogenesis
12/08/2011	US20110300146 Anti-cmet antagonists
12/08/2011	US20110300144 Methods and compositions for diagnosis and treatment of cancer
12/08/2011	US20110300137 Use of lumefantrine and related compounds in the treatment of cancer
12/08/2011	US20110300135 Method and formulation for reducing aggregation of a macromolecule under physiological conditions
12/08/2011	US20110300132 4-aminoquinazoline prodrugs
12/08/2011	US20110300131 Detection and treatment of pancreatic, ovarian and other cancers
12/08/2011	US20110300128 Use of foxp2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes
12/08/2011	US20110300125 Compositions and methods for combined therapy of disease
12/08/2011	US20110300114 METHOD OF CELL CULTURE AND METHOD OF TREATMENT COMPRISING A vEPO PROTEIN VARIANT
12/08/2011	US20110300109 Compositions and methods for treating cancer
12/08/2011	US20110300105 Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo
12/08/2011	US20110300099 Multi-level specific targeting of cancer cells
12/08/2011	US20110300098 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/08/2011	US20110300069 Methods of Using Labeled Ligands Having Human CD4 Specificity
12/08/2011	US20110300068 Agent for prophylaxis or treatment of cancer
12/08/2011	US20110300067 Methods for increasing efficacy of radioimmunotherapy of melanoma
12/08/2011	US20110300066 Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases
12/08/2011	DE102010022926A1 Mikrokapsel zur lokalen Behandlung eines Tumors, Verfahren zur Positionierung eines magnetische Nanopartikel an einen Zielort führenden und/oder an dem Zielort haltenden magnetischen Gradientenfeldes und Vorrichtung zur Positionierung eines magnetischen Gradientenfeldes Microcapsule for the local treatment of a tumor, method for positioning a magnetic nanoparticles leading to a destination and / or holding at the target location and magnetic gradient field apparatus for positioning a magnetic gradient field
12/08/2011	CA2836725A1 Materials and methods for diagnosing and predicting the course of prostate cancer
12/08/2011	CA2836413A1 Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
12/08/2011	CA2801801A1 Novel pharmaceutical compounds
12/08/2011	CA2801645A1 Methods of treatment of pancreatic cancer
12/08/2011	CA2801448A1 Cancer treatment with wortmannin analogs
12/08/2011	CA2801426A1 Combination cancer therapies with wortmannin analogs
12/08/2011	CA2801417A1 Optically active dibenzylamine derivative, and method for preparing thereof
12/08/2011	CA2801314A1 Methods of treating bladder cancer
12/08/2011	CA2801264A1 Novel anti-cmet antibody
12/08/2011	CA2801237A1 Rhamm binding peptides
12/08/2011	CA2801167A1 Xyxin fragment biomarker for diagnosis of colon cancer
12/08/2011	CA2801061A1 Benzoquinolone inhibitors of vmat2
12/08/2011	CA2801003A1 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
12/08/2011	CA2801001A1 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
12/08/2011	CA2800913A1 The use of inhibitors of bruton's tyrosine kinase (btk)
12/08/2011	CA2800898A1 Phosphaplatins and their use for treatment of cancers
12/08/2011	CA2800863A1 Method for producing tumor cell
12/08/2011	CA2800747A1 Rhenium complexes and their pharmaceutical use
12/08/2011	CA2800741A1 Mitochondrial penetrating peptides as carriers for anticancer compounds
12/08/2011	CA2800664A1 Cytochrome p450 inhibitors and uses thereof
12/08/2011	CA2800523A1 Purinone derivative
12/08/2011	CA2799972A1 Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
12/08/2011	CA2799653A1 Substituted isoquinolines and their use as tubulin polymerization inhibitors
12/08/2011	CA2799066A1 Method for cancer therapy
12/08/2011	CA2796620A1 Injectable formulation
12/08/2011	CA2793601A1 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
12/07/2011	EP2392677A2 Combined use of prame inhibitors and hdac inhibitors
12/07/2011	EP2392594A1 N-terminally monopegylated polypeptides and process for their preparation
12/07/2011	EP2392593A2 Differential in tumour gene products and use of same
12/07/2011	EP2392586A1 Binding peptidomimetics and uses of the same
12/07/2011	EP2392580A1 2'-fluoronucleosides
12/07/2011	EP2392576A1 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
12/07/2011	EP2392574A1 Indolyl pyrrolidines for the treatment of cancer
12/07/2011	EP2392565A1 c-Met modulators and methods of use
12/07/2011	EP2392564A1 c-Met modulators and methods of use
12/07/2011	EP2392562A1 Structural carotenoid analogs for the inhibition and amelioration of disease
12/07/2011	EP2392341A1 Compositions for use in treating myelodysplastic syndrome
12/07/2011	EP2392338A1 Prophylactic or therapeutic agent for diseases associated with abnormal bone metabolism
12/07/2011	EP2392337A2 Use of 24-norUDCA
12/07/2011	EP2392330A1 Compositions for use in treating myelodysplastic syndrome
12/07/2011	EP2392329A1 Compositions for use in treating myelodysplastic syndrome
12/07/2011	EP2392324A1 Rhenium complexes and their pharmaceutical use
12/07/2011	EP2392323A1 Prostate cancer progression inhibitor and progression inhibition method
12/07/2011	EP2391649A1 Tslp promotes immune evasion and persistence of viruses
12/07/2011	EP2391630A2 Anti-cancer protein-platinum conjugates
12/07/2011	EP2391605A1 Scriptaid isosteres and their use in therapy
12/07/2011	EP2391378A1 Use of a fragment of rasgap peptide in the treatment or prevention of metastasis
12/07/2011	EP2391367A1 Nampt and vitamin b3 for treating or preventing diseases
12/07/2011	EP2391363A2 Compositions and methods for the treatment of cancer
12/07/2011	EP2391358A1 Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
12/07/2011	EP2158205B1 3,3-spiroindolinone derivatives as anticancer agents
12/07/2011	EP1965790B1 Metabolites of wortmannin analogs and methods of using the same
12/07/2011	EP1957477B1 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
12/07/2011	EP1945665B1 Antibody-based therapeutics with enhanced adcc activity
12/07/2011	EP1802291B1 Calixarene-based peptide conformation mimetics, methods of use, and methods of making
12/07/2011	EP1718323B1 Binding peptidomimetics and uses of the same
12/07/2011	EP1660467B1 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazole compounds useful as protein kinase inhibitors
12/07/2011	CN1875973B 一种含N<sub>3</sub>-邻甲苯甲酰基氟尿嘧啶的药物组合物及其脂质体制剂 Containing N <sub> 3 </ sub> - o-benzoyl-fluorouracil pharmaceutical compositions and liposomal formulations
12/07/2011	CN1843504B 一种白蛋白毫微球组合药物及其制备和使用方法 One kind of albumin nanospheres combination of drugs and their preparation and use
12/07/2011	CN1826324B 吲唑、苯并异唑和苯并异噻唑激酶抑制剂 Indazole, benzoisoxazole oxazole and benzisothiazole kinase inhibitors
12/07/2011	CN1527698B 控释可生物降解的凝胶基质 Controlled release biodegradable gel matrix
12/07/2011	CN1494425B 用作治疗剂的羧酰胺衍生物 As therapeutic agents carboxamide derivatives
12/07/2011	CN102272306A 抗-Siglec-15抗体 Anti -Siglec-15 antibody
12/07/2011	CN102272157A 用于抑制cripto/grp78复合物形成和信号的组合物和方法 Compositions and methods for inhibiting cripto / grp78 complex formation and signals
12/07/2011	CN102272134A Toll样受体调节剂 Toll-like receptor modulators
12/07/2011	CN102272131A 哒嗪酮衍生物 Pyridazinones
12/07/2011	CN102272129A 硫酸化c-糖苷及其分离方法以及合成方法 C- glucoside sulfated and separation and synthesis method
12/07/2011	CN102272125A 哒嗪酮衍生物 Pyridazinone derivatives
12/07/2011	CN102272124A 舒尼替尼苹果酸盐的新晶形 The new crystalline form of sunitinib malate
12/07/2011	CN102272121A 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1，6-二氢-哒嗪-3-基)-苄腈盐酸盐的新型多晶型物及其制备方法 3- (1- {3- [5- (1-methyl - piperidin-4-yl-methoxy) - pyrimidin-2-yl] - benzyl} -6-oxo-1,6-dihydro- - 3-yl) - benzonitrile hydrochloride novel polymorphs and its preparation method
12/07/2011	CN102272112A 苯并噻唑酮衍生物 Benzothiazole derivatives
12/07/2011	CN102271711A 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂 Each maintaining graft-versus-tumor effect of immune reconstitution accelerator or infection prevention agent

1 ... 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 ... 2211